{
    "title": "Accera's Alzheimer's trial fails, in yet another setback for disease",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4267770/Acceras-Alzheimers-trial-fails-setback-disease.html",
    "date": "2017-02-28",
    "keywords": [
        "accera",
        "drug",
        "food",
        "disease",
        "company",
        "inc",
        "latestage",
        "study",
        "treatment",
        "trial",
        "cause",
        "brain",
        "formulation",
        "bioavailability",
        "stacey",
        "groverfeb",
        "tuesday",
        "list",
        "pursuit",
        "mindwasting",
        "improvement",
        "placebo",
        "form",
        "announcement",
        "merck",
        "amp",
        "co",
        "verubecestat",
        "chance",
        "class",
        "bace1",
        "enzyme",
        "formation",
        "toxic",
        "amyloid",
        "protein",
        "mechanism",
        "biogen",
        "novartis",
        "collaboration",
        "amgen",
        "incbut",
        "build",
        "diagnosis",
        "ability",
        "deficit",
        "rise",
        "deposition",
        "chief",
        "executive",
        "multibillion",
        "salesafter",
        "midstage",
        "change",
        "degree",
        "blood",
        "saidwe",
        "endpoint",
        "administration",
        "ceo",
        "product",
        "management",
        "work",
        "principle",
        "differ",
        "taste",
        "format",
        "saidin",
        "fda",
        "axona",
        "definition",
        "issue",
        "market",
        "reporting",
        "grover",
        "bengaluru",
        "editing",
        "savio",
        "dsouza"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}